IOVA
IOVANCE BIOTHERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$14.21
+4.33%Year over year
Reported trailing growth
- Revenue
- +34.5%
- EBITDA
- +30.5%
- EBIT
- +27.9%
- EPS
- +40.7%
- Free cash flow
- +8.4%
- Operating cash flow
- +12.9%
Forward estimates
Based on analyst estimates
- Revenue
- +73.1%
- EBITDA
- +74.0%
- EPS
- +63.3%
Three-year CAGR
- Revenue
- +1388.7%
- EBITDA
- -5.9%
- EBIT
- -0.7%
- Net income
- -5.1%
- EPS
- +14.8%
- Free cash flow
- +7.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026